Endocrine
Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials
Meta-analysis of randomised trialsInterventions
Declared no competing interests
- GLP-1 receptor agonists
- GLP-1 receptor agonists + SGLT2 inhibitors
- GLP-1 and incretin signalling
- Heart failure
- Atherosclerotic cardiovascular disease
- Humans
The paper
Vivekananda Institute of Medical Sciences; Institute of Post Graduate Medical Education and Research
Endocrine, 19 Aug 2026